NV-QUECTEL-WIRELESS
4.1.2023 14:01:53 CET | Business Wire | Press release
CES, Quectel Wireless Solutions, a global IoT and automotive solutions provider, today announces its new automotive grade 5G NR modules, the AG59x series. The new modules deliver a wide range of enhancements including multi-gigabit cellular connectivity, C-V2X PC5 direct communications, improved location services, a high-performance multicore application processor as well as strengthened security, making it an ideal solution in supporting the next generation automotive applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230104005509/en/
(Graphic: Business Wire)
Based on the AEC-Q100 qualified Qualcomm chipsets, the new range of modules include the AG59xH series, which integrates the Qualcomm SA525M and the AG59xE series featuring the Qualcomm SA522M inside. Similar to Quectel’s other automotive products, the AG59x modules comply with the international IATF 16949:2016 automotive quality management system to address the demanding requirements of automotive devices. Featuring high robustness, the AG59x series delivers strong performance even under high temperature environments.
“We are very excited to bring the highly anticipated 5G NR Release 16 module to global automotive markets. Its significant improvements in latency and ultra-reliability are critical in supporting autonomous driving,” said Manfred Lindacher, Vice President of Global Sales, Automotive International, Quectel Wireless Solutions. “Combined with its many other advantages, our AG59x series will be an excellent choice for a wide range of automotive applications including telematics boxes, telematics control units, C-V2X systems, on-board units, and roadside units.”
Meeting the 3GPP Release 16 specification and supporting both 5G NR standalone (SA) and non-standalone (NSA) modes, the AG59x modules are backward-compatible with existing LTE, WCDMA and GSM networks, allowing them to be connected in areas without current 5G NR deployment. Additionally, its Dual SIM Dual Standby (DSDS) technology can help tackle poor signal coverage when needed.
The AG59x supports 4 x 4 downlink multiple input multiple output (MIMO) technology which greatly improves wireless communication performance and optimizes data speeds. The AG59xH delivers maximum downlink rates of 4.3Gbps and uplink rates of 1Gbps for 5G NR, while the AG59xE provides up to 2.4Gbps peak downlink rate and 550Mbps uplink rate. Their faster data speeds ensure that user emergency data and diagnostic data can be transferred in real time for increased reliability.
Supporting optional C-V2X PC5 direct communications, the AG59x brings superior performance in vehicle-to-vehicle (V2V) and vehicle-to-roadside infrastructure (V2I) communications for improved traffic efficiency and safety. The module integrates a powerful application processor with up to 20KDMIPS computing power available to run C-V2X stack and applications. It also has an integrated ECDSA engine fulfill C-V2X verification capability.
Additionally, the highly integrated AG59x module provides flexible GNSS positioning services including L1+L5 / L1+L2 (optional) dual frequency GNSS, dead reckoning (DR), and PPE + Data Correction Service to achieve quick and precise location positioning services.
Available in LGA packages, the AG59x is pin-to-pin compatible with Quectel’s previous generation 5G NR automotive modules AG55xQ and AG57xQ, which allows global OEM and Tier 1 customers to upgrade their devices easily and seamlessly through a simple drop-in replacement. The AG59x provides a variety of interfaces including PCIe 3.0, USB 2.0 & 3.1, SDIO, I2S, SPI, I2C, UART, PCM, ADC, (U)SIM, 1PPS, GPIOs. It also supports RGMII and SGMII interfaces at the same time which greatly improves the adaptability of in-vehicle Ethernet.
The Quectel AG59x series is complemented by its range of high-performance antennas, already in use in the autonomous car market. Customized antennas are also supplied to fit for various vehicle setup environments. In particular, Quectel’s range of combo antennas, which integrate multiple technologies such as 5G, 4G, and GNSS, offer a highly flexible and reliable antenna solution for automotive applications.
Engineering samples of the AG59x modules will be available in the first half of 2023, with multiple variants targeting global markets.
Find out more about this module series at CES 2023 on booth 10862.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services.
Our growing global team of over 6,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005509/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom